Tissue stem cells can self-renew and differentiate, supplying cells necessary for tissues at various developmental stages. However, detailed analysis in.
Date Time
Researcher identifies way to prevent breast cancer stem-like cells from evading therapy
New research at the University of Alberta has revealed a way to increase the sensitivity to immunotherapy of a rare type of cells within a tumour that are responsible for treatment resistance and breast cancer progression. The study, recently published in the journal Cancer Letters, could pave the way to better treatment outcomes for patients.
The researchers looked at how to use a type of cell called gamma delta T-cells more effectively in immunotherapy to target breast cancer stem-like cells. T-cell immunotherapy is a promising new field, with researchers around the world working to develop treatments that use a patient’s own immune system to fight diseases such as cancer. However, most immunotherapy of this type focuses on the more conventional alpha beta T-cells.
Tissue stem cells can self-renew and differentiate, supplying cells necessary for tissues at various developmental stages. However, detailed analysis in vivo is difficult, so the molecular mechanisms underlying the stemness of gastric tissue stem cells have remained a mystery. Here, by using organoids that mimic tissue structure and function in vivo and GeCKO screening to inactivate arbitrary genes,
Press release content from Business Wire. The AP news staff was not involved in its creation.
Indapta Therapeutics Announces Key Management Team Appointments to Advance into Clinical Trials in 2021
February 3, 2021 GMT
SAN FRANCISCO (BUSINESS WIRE) Feb 3, 2021
Indapta Therapeutics Inc. (“Indapta”), a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers, today announced the appointments of Lori Kunkel, M.D., as its Senior Clinical Advisor, Robert Sikorski, M.D., Ph.D., as its Founding Chief Medical Officer, and Jim Weiss as a member of its Board of Directors.